No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 7, 2010, Pages 2884-2889

  Peterson, Dylan W ^a   Ando, D Michael ^a   Taketa, Daryl A ^a   Zhou, Hongjun ^a   Dahlquist, Fredrick W ^a   Lew, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Neurotoxicity; NMR; Protein kinase; Proteolysis

Indexed keywords

CALPAIN; CYCLIN DEPENDENT KINASE 5; HISTONE H1; PROTEIN P25; PROTEIN P35; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; IN VITRO STUDY; MICROTUBULE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION;

BLOTTING, WESTERN; ESCHERICHIA COLI; HISTONES; HUMANS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; NERVE TISSUE PROTEINS; NEURONS; PHOSPHORYLATION; TAU PROTEINS;

EID: 77649250664     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0912718107     Document Type: Article

References (54)

1. Ishiguro K, et al. (1991) A serine/threonine proline kinase activity is included in the tau protein kinase fraction forming a paired helical filament epitope. Neurosci Lett 128:195-8.
2. Ishiguro K, et al. (1992) Tau protein kinase I converts normal tau protein into A68-like component of paired helical filaments. J Biol Chem 267:10897-901.
3. Lew J, Beaudette K, Litwin CM, Wang JH (1992) Purification and characterization of a novel proline-directed protein kinase from bovine brain. J Biol Chem 267:13383-90.
4. Lew J, Winkfein RJ, Paudel HK, Wang JH (1992) Brain proline-directed protein kinase is a neurofilament kinase which displays high sequence homology to p34cdc2. J Biol Chem 267:25922-6.
5. Lew J, Wang JH (1995) Neuronal cdc2-like kinase. Trends Biochem Sci 20:33-7.
6. Ishiguro K, et al. (1994) Identification of the 23 kDa subunit of tau protein kinase II as a putative activator of cdk5 in bovine brain. FEBS Lett 342:203-8.
7. Lew J, et al. (1994) A brain-specific activator of cyclin-dependent kinase. Nature 371:423-6.
8. Tsai LH, Delalle I, Caviness VS, Jr, Chae T, Harlow E (1994) p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371:419-23.
9. Uchida T, et al. (1994) Precursor of cdk5 activator, the 23 kDa subunit of tau protein kinase II: its sequence and developmental change in brain. FEBS Lett 355:35-40.
10. Cruz JC, Tsai LH (2004) A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr Opin Neurobiol 14:390-4.
11. Patrick GN, et al. (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615-22.
12. Taniguchi S, et al. (2001) Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett 489:46-50.
13. Takashima A, et al. (2001) Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci Lett 306:37-40.
14. Nguyen KC, Rosales JL, Barboza M, Lee KY (2002) Controversies over p25 in Alzheimer's disease. J Alzheimers Dis 4:123-6.
15. Yoo BC, Lubec G (2001) p25 protein in neurodegeneration. Nature 411:763-4 discussion 764-5.
16. Tandon A, et al. (2003) Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles. J Neurochem 86:572-81.
17. Tseng HC, Zhou Y, Shen Y, Tsai LH (2002) A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett 523:58-62.
18. Otth C, et al. (2002) AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis 4:417-30.
19. Smith PD, et al. (2003) Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. P Natl Acad Sci USA 100:13650-5.
20. Nguyen MD, Lariviere RC, Julien JP (2001) Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 30:135-47.
21. Ahuja HS, Zhu Y, Zakeri Z (1997) Association of cyclin-dependent kinase 5 and its activator p35 with apoptotic cell death. Dev Genet 21:258-67.
22. Zhang J, Krishnamurthy PK, Johnson GV (2002) Cdk5 phosphorylates p53 and regulates its activity. J Neurochem 81:307-13.
23. Lee MS, et al. (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405:360-4.
24. Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH (1998) p35: the neuronalspecific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitinproteasome pathway. J Biol Chem 273:24057-64.
25. Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttila T (2002) Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation. Biochem Biophys Res Commun 298:693-8.
26. Hashiguchi M, Saito T, Hisanaga S, Hashiguchi T (2002) Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J Biol Chem 277:44525-30.
27. Beaudette KN, Lew J, Wang JH (1993) Substrate specificity characterization of a cdc2-like protein kinase purified from bovine brain. J Biol Chem 268:20825-30.
28. Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E (1993) Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 336:417-24.
29. Ishiguro K, et al. (1995) Analysis of phosphorylation of tau with antibodies specific for phosphorylation sites. Neurosci Lett 202:81-4.
30. Paudel HK, Lew J, Ali Z, Wang JH (1993) Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J Biol Chem 268:23512-8.
31. Lund ET, McKenna R, Evans DB, Sharma SK, Mathews WR (2001) Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry. J Neurochem 76:1221-32.
32. Illenberger S, et al. (1998) The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol Biol Cell 9:1495-512.
33. Hasegawa M, et al. (1992) Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. J Biol Chem 267:17047-54.
34. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 71:2465-76.
35. Morishima-Kawashima M, et al. (1995) Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem 270:823-9.
36. Hanger DP, et al. (2007) Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 282:23645-54.
37. Watanabe A, et al. (1993) In vivo phosphorylation sites in fetal and adult rat tau. J Biol Chem 268:25712-7.
38. Liu M, et al. (2008) Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors. Biochemistry 47:8367-77.
39. Ahn JS, et al. (2005) Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. Chem Biol 12:811-23.
40. Imahori K, et al. (1998) Possible role of tau protein kinases in pathogenesis of Alzheimer's disease. Neurobiol Aging 19:S93-8.
41. Cornish-Bowden A (1995) Fundamentals of Enzyme Kinetics (Portland Press LTD, London).
42. Ahlijanian MK, et al. (2000) Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA 97:2910-5.
43. Lew J (2003) MAP kinases and CDKs: kinetic basis for catalytic activation. Biochemistry 42:849-56.
44. Amniai L, et al. (2009) Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules. Faseb J 23:1146-52.
45. Stevenson-Lindert LM, Fowler P, Lew J (2003) Substrate specificity of CDK2-cyclin A. What is optimal?. J Biol Chem 278:50956-60.
46. Kusakawa G, et al. (2000) Calpain-dependent proteolytic cleavage of the p35 cyclindependent kinase 5 activator to p25. J Biol Chem 275:17166-72.
47. Sakaue F, et al. (2005) Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39. J Biol Chem 280:31522-9.
48. Maestre C, Delgado-Esteban M, Gomez-Sanchez JC, Bolanos JP, Almeida A (2008) Cdk5 phosphorylates Cdh1 and modulates cyclin B1 stability in excitotoxicity. Embo J 27:2736-45.
49. Zukerberg LR, et al. (2000) Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron 26:633-46.
50. Peterson DW, Zhou H, Dahlquist FW, Lew J (2008) A soluble oligomer of tau associated with fiber formation analyzed by NMR. Biochemistry 47:7393-404.
51. Prowse CN, Hagopian JC, Cobb MH, Ahn NG, Lew J (2000) Catalytic reaction pathway for the mitogen-activated protein kinase ERK2. Biochemistry 39:6258-66.
52. Delaglio F, et al. (1995) nmrPipe-a Multidimensional Spectral Processing System Based On Unix Pipes. J Biomol NMR 6:277-293.
53. Kraulis PJ (1989) ANSIG: A Program for the Assignment of Protein 1H 2D NMR spectra by Interactive Graphics. J Magn Reson 24:627-633.
54. Kraulis PJ, Domaille PJ, Campbell-Burk SL, Van Aken T, Laue ED (1994) Solution structure and dynamics of ras p21.GDP determined by heteronuclear three- and four-dimensional NMR spectroscopy. Biochemistry 33:3515-31.